NMN zwitterion

5-times sit-to-stand, effect size

decreases

the effect size of 5-STS was the largest in the NMN_PM group (d = 0.72)

PMID:35215405 · one of two readings recorded this

5-times sit-to-stand, group × time interaction

modulates, p = 0.04, n = 108

a significant interaction was observed in 5-STS (p = 0.04)

PMID:35215405 · one of two readings recorded this

5-times sit-to-stand, main effect of group

modulates, p = 0.05, n = 108

5-STS showed significant in the main effects of group (p = 0.05)

PMID:35215405 · one of two readings recorded this

5-times sit-to-stand, main effect of time

decreases, p = 0.01, n = 108

Significant main effects of time were observed in 5-STS (p < 0.01) and TUG (p < 0.01)

PMID:35215405 · one of two readings recorded this

5-times sit-to-stand, Post vs Pre

decreases, n = 108

The post hoc analysis revealed significantly improved 5-STS in Post compared with Pre in all groups

PMID:35215405 · one of two readings recorded this

drowsiness, effect size

decreases

the NMN_PM group showed a medium effect size (d = 0.64) in drowsiness

PMID:35215405 · one of two readings recorded this

drowsiness (Jikaku-sho shirabe), group × time interaction

modulates, p = 0.02, n = 108

The interactions of fatigue with drowsiness were significant (p = 0.02)

PMID:35215405 · one of two readings recorded this

drowsiness, main effect of time

decreases, p = 0.01, n = 108

Drowsiness (p < 0.01), instability (p < 0.01), dullness (p = 0.03), and total fatigue score (p < 0.01) showed significant in the main effects of time

PMID:35215405 · one of two readings recorded this

drowsiness, Mid and Post vs Pre

decreases

According to the post hoc analysis, the improvement in the drowsiness of Mid and Post was more significant than that of Pre in both NMN_PM and Placebo_PM groups

PMID:35215405 · one of two readings recorded this

dullness, main effect of time

decreases, p = 0.03, n = 108

Drowsiness (p < 0.01), instability (p < 0.01), dullness (p = 0.03), and total fatigue score (p < 0.01) showed significant in the main effects of time

PMID:35215405 · one of two readings recorded this

instability, main effect of time

decreases, p = 0.01, n = 108

Drowsiness (p < 0.01), instability (p < 0.01), dullness (p = 0.03), and total fatigue score (p < 0.01) showed significant in the main effects of time

PMID:35215405 · one of two readings recorded this

Jikaku-sho shirabe fatigue questionnaire (drowsiness subscale and total score), PSQI global score, and 5-times sit-to-stand, timed up and go and grip strength in four arms (NMN 250 mg morning, NMN 250 mg evening, placebo morning, placebo evening) over 12 weeks

Not recorded as a finding: the result compares a group with itself, not with a control

According to the post hoc analysis, the improvement in the drowsiness of Mid and Post was more significant than that of Pre in both NMN_PM and Placebo_PM groups.

PMID:35215405 · one of two readings recorded this

PSQI daytime dysfunction score, effect size

decreases

the effect sizes of sleep latency (d = 0.56), daytime dysfunction score (d = 0.72), sleep quality score (d = 0.80), and total PSQI global score (d = 0.68) in the NMN_PM group were the largest among the four groups

PMID:35215405 · one of two readings recorded this

PSQI global score, effect size

decreases

the effect sizes of sleep latency (d = 0.56), daytime dysfunction score (d = 0.72), sleep quality score (d = 0.80), and total PSQI global score (d = 0.68) in the NMN_PM group were the largest among the four groups

PMID:35215405 · one of two readings recorded this

PSQI sleep duration, sleep disturbance, daytime dysfunction, sleep quality and global score, main effect of time

decreases, p = 0.01, n = 108

there were significant main effects (p < 0.01) of time in sleep duration, sleep disturbance score, daytime dysfunction score, sleep quality score, and total PSQI global score

PMID:35215405 · one of two readings recorded this

PSQI sleep latency, effect size

decreases

the effect sizes of sleep latency (d = 0.56), daytime dysfunction score (d = 0.72), sleep quality score (d = 0.80), and total PSQI global score (d = 0.68) in the NMN_PM group were the largest among the four groups

PMID:35215405 · one of two readings recorded this

PSQI sleep quality, group × time interaction

no effect, n = 108

There was no statistically significant interaction in sleep quality as assessed by the PSQI

PMID:35215405 · one of two readings recorded this

PSQI sleep quality score, effect size

decreases

the effect sizes of sleep latency (d = 0.56), daytime dysfunction score (d = 0.72), sleep quality score (d = 0.80), and total PSQI global score (d = 0.68) in the NMN_PM group were the largest among the four groups

PMID:35215405 · one of two readings recorded this

sleep quality, Pittsburgh Sleep Quality Index global score; fatigue by Jikaku-sho shirabe; 5-times sit-to-stand, timed up and go, 5-m habitual walk, grip strength; 12 weeks of 250 mg NMN or placebo, morning or evening (four arms)

no effect

Not recorded as a finding: the supporting sentence never names the compound

There was no statistically significant interaction in sleep quality as assessed by the PSQI.

PMID:35215405 · one of two readings recorded this

timed up and go, effect size

decreases

the NMN_PM group showed a medium effect size (d = 0.54) in TUG

PMID:35215405 · one of two readings recorded this

timed up and go, main effect of time

decreases, p = 0.01, n = 108

Significant main effects of time were observed in 5-STS (p < 0.01) and TUG (p < 0.01)

PMID:35215405 · one of two readings recorded this

total fatigue score, main effect of time

decreases, p = 0.01, n = 108

Drowsiness (p < 0.01), instability (p < 0.01), dullness (p = 0.03), and total fatigue score (p < 0.01) showed significant in the main effects of time

PMID:35215405 · one of two readings recorded this

anthropometric, hematological, biochemical, urine and body composition parameters

no effect

Oral administration of β-NMN did not result in changes exceeding physiological variations in multiple clinical trials, including anthropometry, hematological, biochemical, urine, and body composition analyses

PMID:36002548 · one of two readings recorded this

safety of 1250 mg oral beta-NMN once daily for up to 4 weeks: anthropometry, hematological, biochemical, urine and body composition analyses; adverse events

no effect

Not recorded as a finding: no estimate is reported anywhere

Oral administration of β-NMN did not result in changes exceeding physiological variations in multiple clinical trials, including anthropometry, hematological, biochemical, urine, and body composition analyses.

PMID:36002548 · one of two readings recorded this

safety of beta-NMN 1250 mg orally once daily for up to 4 weeks versus placebo: anthropometry, hematological, biochemical, urine and body composition analyses, and severe adverse events

no effect

Not recorded as a finding: no estimate is reported anywhere

Oral administration of β-NMN did not result in changes exceeding physiological variations in multiple clinical trials, including anthropometry, hematological, biochemical, urine, and body composition analyses.

PMID:36002548 · one of two readings recorded this

HOMA-IR

no effect, n = 80

The HOMA-IR showed no statistically significant differences for all NMN-treated groups as compared to placebo at day 60

PMID:36482258 · one of two readings recorded this

blood biological age

decreases, p = 0.05, n = 80

The blood biological age increased significantly in the placebo group and stayed unchanged in all NMN-treated groups at day 60, which resulted in a significant difference between the treated groups and placebo (all p < 0.05)

PMID:36482258 · one of two readings recorded this

blood NAD concentration

increases, p = 0.001, n = 80

Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline (all p ≤ 0.001)

PMID:36482258 · one of two readings recorded this

blood NAD concentration

increases, p = 0.001, n = 80

Blood NAD concentrations were statistically significantly increased among all NMN-treated groups at day 30 and day 60 when compared to both placebo and baseline (all p ≤ 0.001)

PMID:36482258 · one of two readings recorded this

SF-36 score change

increases, p = 0.05, n = 80

The change of SF-36 scores at day 30 and day 60 indicated statistically significantly better health of all three treated groups when compared to the placebo group (p < 0.05)

PMID:36482258 · one of two readings recorded this

walking distance increase, six-minute walking test

increases, p = 0.01, n = 80

Walking distance increase during the six-minute walking test was statistically significantly higher in the 300 mg, 600 mg, and 900 mg groups compared to placebo at both days 30 and 60 (all p < 0.01)

PMID:36482258 · one of two readings recorded this

walking distance increase, six-minute walking test

increases, p = 0.01, n = 80

Walking distance increase during the six-minute walking test was statistically significantly higher in the 300 mg, 600 mg, and 900 mg groups compared to placebo at both days 30 and 60 (all p < 0.01)

PMID:36482258 · one of two readings recorded this

estradiol

no effect, p = 0.361, n = 34

Estradiol (pg/mL) | 75.2 ± 87.2 | 101.7 ± 123.8 | 35.1 | 81.0 ± 121.1 | 78.3 ± 82.4 | − 3.3 | 0.361

PMID:36797393 · one of two readings recorded this

progesterone

no effect, p = 0.86, n = 34

Progesterone (ng/mL) | 2.1 ± 4.4 | 3.0 ± 4.8 | 43.6 | 2.4 ± 6.2 | 1.9 ± 4.4 | − 22.1 | 0.860

PMID:36797393 · one of two readings recorded this

testosterone

no effect, p = 0.933, n = 34

Testosterone (ng/dL) | 143.1 ± 193.7 | 139.7 ± 187.8 | − 2.4 | 212.2 ± 249.1 | 208.2 ± 257.6 | − 1.9 | 0.933

PMID:36797393 · one of two readings recorded this

triglyceride

no effect, p = 0.804, n = 34

Triglyceride (mg/dL) | 86.4 ± 54.7 | 83.1 ± 46.6 | − 3.8 | 69.1 ± 35.9 | 70.6 ± 42.1 | 2.1 | 0.804

PMID:36797393 · one of two readings recorded this

hemoglobin

no effect, p = 0.971, n = 34

Hemoglobin (g/dL) | 13.6 ± 1.0 | 13.4 ± 0.9 | − 2.0 | 13.6 ± 1.8 | 13.3 ± 1.8 | − 2.0 | 0.971

PMID:36797393 · one of two readings recorded this

AST

no effect, p = 0.472, n = 34

AST (U/L) | 25.3 ± 7.9 | 23.1 ± 6.1 | − 8.6 | 22.8 ± 7.5 | 20.8 ± 5.4 | − 9.0 | 0.472

PMID:36797393 · one of two readings recorded this

ALT

no effect, p = 0.193, n = 34

ALT (U/L) | 24.9 ± 12.2 | 22.4 ± 9.8 | − 10.4 | 20.6 ± 10.9 | 17.4 ± 8.3 | − 16.0 | 0.193

PMID:36797393 · one of two readings recorded this

ankle-brachial index, average

no effect, p = 0.367, n = 34

Average | 1.11 ± 0.04 | 1.12 ± 0.06 | 1.8 | 1.10 ± 0.06 | 1.11 ± 0.06 | 0.6 | 0.367

PMID:36797393 · one of two readings recorded this

ankle-brachial index, left

no effect, p = 0.359, n = 34

Left | 1.10 ± 0.06 | 1.13 ± 0.06 | 2.2 | 1.10 ± 0.07 | 1.11 ± 0.08 | 0.6 | 0.359

PMID:36797393 · one of two readings recorded this

ankle-brachial index, right

no effect, p = 0.623, n = 34

Right | 1.11 ± 0.04 | 1.12 ± 0.06 | 1.3 | 1.10 ± 0.07 | 1.11 ± 0.07 | 0.6 | 0.623

PMID:36797393 · one of two readings recorded this

baPWV average, change from baseline in NMN group

decreases, n = 17

The average baPWV values in the NMN intake group tended to decrease by 25.1 ± 14.5 cm/s

PMID:36797393 · one of two readings recorded this

baPWV, average

no effect, p = 0.097, n = 34

Average | 1338.1 ± 219.9 | 1344.5 ± 212.9 | 0.5 | 1208.0 ± 152.2 | 1182.9 ± 145.3 | − 2.1 | 0.097

PMID:36797393 · one of two readings recorded this

baPWV, left

no effect, p = 0.147, n = 34

Left | 1343.6 ± 216.5 | 1349.4 ± 211.7 | 0.4 | 1205.1 ± 153.6 | 1189.5 ± 131.1 | − 1.3 | 0.147

PMID:36797393 · one of two readings recorded this

baPWV, right

no effect, p = 0.07, n = 34

Right | 1332.7 ± 227.1 | 1339.6 ± 217.1 | 0.5 | 1211.0 ± 153.8 | 1176.4 ± 161.7 | − 2.9 | 0.070

PMID:36797393 · one of two readings recorded this

baPWV

decreases

in subjects with above-average BMI or blood glucose levels, baPWV values in the NMN intake group were significantly decreased after the test period compared to the placebo group

PMID:36797393 · one of two readings recorded this

baPWV

decreases

in subjects with above-average BMI or blood glucose levels, baPWV values in the NMN intake group were significantly decreased after the test period compared to the placebo group

PMID:36797393 · one of two readings recorded this

baPWV

no effect

In the analyses of subjects with higher-than-mean systolic or diastolic blood pressure, there was no significant change in baPWV values between the groups during the test period

PMID:36797393 · one of two readings recorded this

blood glucose

no effect, p = 0.324, n = 34

Blood glucose level (mg/dL) | 90.1 ± 5.9 | 89.9 ± 6.5 | − 0.2 | 87.0 ± 4.5 | 89.0 ± 5.6 | 2.3 | 0.324

PMID:36797393 · one of two readings recorded this

BMI

no effect, p = 0.273, n = 34

BMI (kg/M2) | 21.5 ± 2.3 | 21.5 ± 2.2 | 0.0 | 21.7 ± 4.2 | 21.9 ± 4.3 | 0.8 | 0.273

PMID:36797393 · one of two readings recorded this

body weight

no effect, p = 0.324, n = 34

Weight (kg) | 57.8 ± 8.4 | 57.6 ± 7.8 | − 0.4 | 61.7 ± 18.5 | 61.9 ± 18.6 | 0.4 | 0.324

PMID:36797393 · one of two readings recorded this

brachial-ankle pulse wave velocity (baPWV) and ankle-brachial index after 12 weeks of NMN 250 mg/day versus placebo in healthy middle-aged adults; also serum nicotinamide, NMN and NAD+, hematology, clinical chemistry and hormones (reported in tables or in sentences that do not name NMN as the contrast)

no effect, average baPWV difference between groups not significant, p = 0.097

Not recorded as a finding: a node exists but the paper states a different instrument or population

However, no significant difference was observed in the average baPWV values between the two groups (p = 0.097).

PMID:36797393 · one of two readings recorded this

DHEA-S

no effect, p = 0.166, n = 34

DHEA-S (ng/mL) | 1610.1 ± 566.1 | 1864.2 ± 751.2 | 15.8 | 1875.8 ± 1087.3 | 1923.1 ± 972.4 | 2.5 | 0.166

PMID:36797393 · one of two readings recorded this

diastolic blood pressure

no effect, p = 0.196, n = 34

Diastolic (mmHg) | 76.0 ± 12.4 | 79.4 ± 10.3 | 4.4 | 69.8 ± 15.0 | 70.8 ± 15.5 | 1.5 | 0.196

PMID:36797393 · one of two readings recorded this

γ-GTP

no effect, p = 0.956, n = 34

γ-GTP (U/L) | 32.4 ± 19.2 | 29.6 ± 18.7 | − 8.5 | 37.1 ± 46.2 | 33.0 ± 37.3 | − 11.1 | 0.956

PMID:36797393 · one of two readings recorded this

HDL-cholesterol

no effect, p = 0.885, n = 34

HDL-cholesterol (mg/dL) | 73.5 ± 16.5 | 74.2 ± 16.9 | 1.0 | 72.2 ± 15.5 | 73.5 ± 16.2 | 1.7 | 0.885

PMID:36797393 · one of two readings recorded this

hematocrit

no effect, p = 0.686, n = 34

Hematocrit (%) | 42.7 ± 2.9 | 41.6 ± 2.9 | − 2.7 | 42.6 ± 4.1 | 41.7 ± 4.1 | − 2.1 | 0.686

PMID:36797393 · one of two readings recorded this

LDL-cholesterol

no effect, p = 0.863, n = 34

LDL-cholesterol (mg/dL)) | 122.7 ± 54.1 | 121.3 ± 47.6 | − 1.2 | 119.9 ± 25.9 | 120.3 ± 24.9 | 0.3 | 0.863

PMID:36797393 · one of two readings recorded this

proportion consuming other supplements

the percentage of people consuming other supplements in the placebo and NMN groups was 35.1% and 32.4%, respectively

PMID:36797393 · one of two readings recorded this

red blood cell count

no effect, p = 0.376, n = 34

RBC (counts × 104//µL) | 454.3 ± 42.7 | 442.1 ± 36.8 | − 2.7 | 452.5 ± 41.9 | 445.8 ± 41.7 | − 1.5 | 0.376

PMID:36797393 · one of two readings recorded this

serum cortisol

no effect, p = 0.422, n = 34

Serum cortisol (µg/dL) | 8.4 ± 2.6 | 7.9 ± 2.5 | − 6.6 | 8.1 ± 3.1 | 7.2 ± 1.9 | − 11.0 | 0.422

PMID:36797393 · one of two readings recorded this

serum nicotinamide (NAM) at baseline

unclear, p = 0.001

at baseline, serum NAM levels significantly differed between the placebo and NMN groups (p = 0.001)

PMID:36797393 · one of two readings recorded this

serum nicotinamide (NAM) concentration by isotope dilution LC-MS/MS; also brachial-ankle pulse wave velocity (baPWV) by Omron waveform analyzer, SIRT1 mRNA, urinary 8-OHdG, skin AGEs

increases, p = 0.037

Not recorded as a finding: this platform holds no node for the endpoint

The analysis of covariance (ANCOVA) with baseline score as a covariate revealed that NAM levels in the NMN intake group were significantly increased after the intervention compared to the placebo group (p = 0.037).

PMID:36797393 · one of two readings recorded this

serum nicotinamide (NAM), within-group change in NMN group

increases, p = 0.006, n = 17

serum NAM in the NMN group significantly increased after 12 weeks (p = 0.006), while that in the placebo group significantly decreased after intervention (p = 0.014)

PMID:36797393 · one of two readings recorded this

serum nicotinamide (NAM), within-group change in placebo group

decreases, p = 0.014, n = 17

serum NAM in the NMN group significantly increased after 12 weeks (p = 0.006), while that in the placebo group significantly decreased after intervention (p = 0.014)

PMID:36797393 · one of two readings recorded this

serum nicotinamide (NAM)

increases, p = 0.037, n = 34

NAM (ng/mL) | 14.9 ± 3.8 | 10.9 ± 4.8 | − 26.8 | 10.4 ± 3.5 | 16.5 ± 6.3 | 57.6 | 0.037*

PMID:36797393 · one of two readings recorded this

SIRT1 mRNA level

no effect, p = 0.211, n = 34

SIRT1 mRNA level | 3.6 ± 1.0 | 4.9 ± 1.4 | 38.5 | 3.6 ± 1.6 | 4.3 ± 2.0 | 18.8 | 0.211

PMID:36797393 · one of two readings recorded this

skin AGEs

no effect, p = 0.283, n = 34

AGEs (a.u.) | 0.6 ± 0.1 | 0.5 ± 0.1 | − 3.9 | 0.5 ± 0.1 | 0.5 ± 0.1 | 7.6 | 0.283

PMID:36797393 · one of two readings recorded this

systolic blood pressure

no effect, p = 0.414, n = 34

Systolic (mmHg) | 124.3 ± 15.0 | 127.1 ± 13.0 | 2.2 | 118.0 ± 16.2 | 119.2 ± 18.2 | 1.0 | 0.414

PMID:36797393 · one of two readings recorded this

urinary 8-OHdG

no effect, p = 0.735, n = 34

8-OHdG (ng/mg creatinine) | 7.1 ± 2.4 | 7.3 ± 2.6 | 2.3 | 7.9 ± 2.6 | 8.0 ± 3.3 | 0.7 | 0.735

PMID:36797393 · one of two readings recorded this

white blood cell count

no effect, p = 0.838, n = 34

WBC (counts/µL) | 6015.3 ± 1876.9 | 5999.4 ± 1732.2 | − 0.3 | 5937.6 ± 1552.5 | 5853.5 ± 1871.5 | − 1.4 | 0.838

PMID:36797393 · one of two readings recorded this

4-m walking time, secondary endpoint at 12 weeks

decreases

Not recorded as a finding: No walking-time node in the outcome list.

At secondary outcomes, after 12 weeks of NMN intake, the NMN group had a significantly shorter 4-m walking time than the placebo group as well as significantly higher blood levels of NAD + and its metabolites.

PMID:38789831 · one of two readings recorded this

4-m walking time, secondary outcome

decreases

Not recorded as a finding: No outcome node for 4-m walking time

At secondary outcomes, after 12 weeks of NMN intake, the NMN group had a significantly shorter 4-m walking time than the placebo group as well as significantly higher blood levels of NAD + and its metabolites.

PMID:38789831 · one of two readings recorded this

4-m walking time

decreases, n = 60

after 12 weeks of NMN intake, the NMN group had a significantly shorter 4-m walking time than the placebo group

PMID:38789831 · one of two readings recorded this

blood NAD+ and metabolites

increases, n = 60

after 12 weeks of NMN intake, the NMN group had a significantly shorter 4-m walking time than the placebo group as well as significantly higher blood levels of NAD + and its metabolites

PMID:38789831 · one of two readings recorded this

correlation of change in 4-m walking time with change in blood NAD+, 2-PY and 4-PY

decreases

A significant negative correlation was observed between the change in the 4-m walking time and the change in blood NAD + , N1-methyl-2-pridone-5-carboxamide (2-PY), and N1-methyl-4-pridone-3-carboxamide (4-PY) at 12 weeks

PMID:38789831 · one of two readings recorded this

PSQI daytime dysfunction and global score

decreases, n = 60

The NMN group had improved sleep quality at 12 weeks relative to the placebo group as evidenced by lower scores for "Daytime dysfunction" and "Global PSQI" on the Pittsburgh Sleep Questionnaire

PMID:38789831 · one of two readings recorded this

stepping test, primary endpoint at 4 and 12 weeks

no effect

Not recorded as a finding: No stepping-test node in the outcome list.

At primary outcome, at both 4 weeks and 12 weeks, the NMN and placebo groups had no significant differences in a stepping test.

PMID:38789831 · one of two readings recorded this

stepping test, primary outcome

no effect

Not recorded as a finding: No outcome node for the stepping test

At primary outcome, at both 4 weeks and 12 weeks, the NMN and placebo groups had no significant differences in a stepping test.

PMID:38789831 · one of two readings recorded this

stepping test

no effect, n = 60

At primary outcome, at both 4 weeks and 12 weeks, the NMN and placebo groups had no significant differences in a stepping test

PMID:38789831 · one of two readings recorded this

stepping test

no effect, n = 60

At primary outcome, at both 4 weeks and 12 weeks, the NMN and placebo groups had no significant differences in a stepping test

PMID:38789831 · one of two readings recorded this

HOMA-IR

no effect

The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile

PMID:39531138 · one of two readings recorded this

fasting glucose

no effect

The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile

PMID:39531138 · one of two readings recorded this

fasting insulin

no effect

The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile

PMID:39531138 · one of two readings recorded this

glycated hemoglobin

no effect

The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile

PMID:39531138 · one of two readings recorded this

lipid profile

no effect

The random-effects meta-analyses indicated no significant benefit of NMN on fasting glucose, fasting insulin, glycated hemoglobin, homeostatic model assessment for insulin resistance and lipid profile

PMID:39531138 · one of two readings recorded this

5-time chair stand test (5CST)

no effect, p = 0.41, n = 2

5CST (n = 2; MD: -0.21, 95%CI: -0.70 - 0.29, I2 = 11%, p = 0.41)

PMID:40275690 · one of two readings recorded this

5-time chair stand test, pooled mean difference

no effect, MD -0.21, 95% CI -0.70 to 0.29, p = 0.41

Not recorded as a finding: No outcome node for 5-time chair stand test

NMN supplementation showed no significant effects on SMI (n = 3; mean difference (MD): -0.42, 95% confidence interval (CI): -0.99 - 0.14, I2 = 63%, p = 0.14), HGS (One study estimating left grip; n = 5; MD: 0.61, 95%CI: -0.89 - 2.10, I2 = 0%, p = 0.42; One study estimating right grip; n = 5; MD: 0.45, 95%CI: -1.06 - 1.96, I2 = 0%, p = 0.56), gait speed (n = 4; MD: -0.01, 95%CI: -0.08 - 0.06, I2 = 0%, p = 0.79), or 5CST (n = 2; MD: -0.21, 95%CI: -0.70 - 0.29, I2 = 11%, p = 0.41).

PMID:40275690 · both readings recorded this

gait speed, pooled mean difference

no effect, MD -0.01, 95% CI -0.08 to 0.06, p = 0.79

Not recorded as a finding: No outcome node for gait speed

NMN supplementation showed no significant effects on SMI (n = 3; mean difference (MD): -0.42, 95% confidence interval (CI): -0.99 - 0.14, I2 = 63%, p = 0.14), HGS (One study estimating left grip; n = 5; MD: 0.61, 95%CI: -0.89 - 2.10, I2 = 0%, p = 0.42; One study estimating right grip; n = 5; MD: 0.45, 95%CI: -1.06 - 1.96, I2 = 0%, p = 0.56), gait speed (n = 4; MD: -0.01, 95%CI: -0.08 - 0.06, I2 = 0%, p = 0.79), or 5CST (n = 2; MD: -0.21, 95%CI: -0.70 - 0.29, I2 = 11%, p = 0.41).

PMID:40275690 · both readings recorded this

gait speed

no effect, p = 0.79, n = 4

gait speed (n = 4; MD: -0.01, 95%CI: -0.08 - 0.06, I2 = 0%, p = 0.79)

PMID:40275690 · one of two readings recorded this

handgrip strength, left grip

no effect, p = 0.42, n = 5

One study estimating left grip; n = 5; MD: 0.61, 95%CI: -0.89 - 2.10, I2 = 0%, p = 0.42

PMID:40275690 · one of two readings recorded this

handgrip strength, right grip

no effect, p = 0.56, n = 5

One study estimating right grip; n = 5; MD: 0.45, 95%CI: -1.06 - 1.96, I2 = 0%, p = 0.56

PMID:40275690 · one of two readings recorded this

knee extension strength, SPPB and thigh muscle mass (narrative synthesis)

no effect

Additionally, our narrative synthesis showed that NMN did not improve knee extension strength, SPPB, or thigh muscle mass

PMID:40275690 · one of two readings recorded this

skeletal muscle index (SMI), pooled mean difference

no effect, MD -0.42, 95% CI -0.99 to 0.14, p = 0.14

Not recorded as a finding: No outcome node for skeletal muscle index

NMN supplementation showed no significant effects on SMI (n = 3; mean difference (MD): -0.42, 95% confidence interval (CI): -0.99 - 0.14, I2 = 63%, p = 0.14), HGS (One study estimating left grip; n = 5; MD: 0.61, 95%CI: -0.89 - 2.10, I2 = 0%, p = 0.42; One study estimating right grip; n = 5; MD: 0.45, 95%CI: -1.06 - 1.96, I2 = 0%, p = 0.56), gait speed (n = 4; MD: -0.01, 95%CI: -0.08 - 0.06, I2 = 0%, p = 0.79), or 5CST (n = 2; MD: -0.21, 95%CI: -0.70 - 0.29, I2 = 11%, p = 0.41).

PMID:40275690 · both readings recorded this

skeletal muscle index (SMI)

no effect, p = 0.14, n = 3

NMN supplementation showed no significant effects on SMI (n = 3; mean difference (MD): -0.42, 95% confidence interval (CI): -0.99 - 0.14, I2 = 63%, p = 0.14)

PMID:40275690 · one of two readings recorded this

triglycerides

increases, n = 80

0.023% (95% CI: 0.011-0.036) higher triglycerides

PMID:41162813 · one of two readings recorded this

uric acid

increases, n = 80

uric acid of 0.02% (95%CI: 0.003-0.038)

PMID:41162813 · one of two readings recorded this

hemoglobin

increases, n = 80

Every 1 nM increase in the NAD level was associated with an increase in hemoglobin of 0.027% (95% CI: 0.01-0.045)

PMID:41162813 · one of two readings recorded this

alanine transaminase

increases, n = 80

0.02% (95% CI: 0.004-0.035) higher alanine transaminase

PMID:41162813 · one of two readings recorded this

aspartate transaminase

increases, n = 80

0.01% (95% CI: 0.0003-0.021) aspartate transaminase

PMID:41162813 · one of two readings recorded this

association of blood NAD level (baseline, and change after 60 days of NMN 300, 600 or 900 mg/d) with blood counts, lipids, liver enzymes and uric acid; post hoc correlational analysis within a randomized trial

increases

Not recorded as a finding: another reason, stated per paper

NMN-induced increases in blood NAD are associated with an increase in RBC parameters, potentially indicating enhanced oxygen-carrying capacity.

PMID:41162813 · one of two readings recorded this

high-density lipoprotein

decreases, n = 80

- 0.009% (95% CI: - 0.015 to - 0.003) lower high-density lipoprotein

PMID:41162813 · one of two readings recorded this

lymphocytes

increases, n = 80

Every 1 nM higher baseline NAD level was associated with 0.24% (95%CI: 0.05-0.44) higher lymphocytes

PMID:41162813 · one of two readings recorded this

mean corpuscular hemoglobin concentration

increases, n = 80

mean corpuscular hemoglobin concentration of 0.016 g/dL (95% CI: 0.008-0.025)

PMID:41162813 · one of two readings recorded this

neutrophils

decreases, n = 80

- 0.36% (95% CI: - 0.57 to - 0.14) lower neutrophils

PMID:41162813 · one of two readings recorded this

red blood cells

increases, n = 80

red blood cells (RBC) of 0.025% (95% CI: 0.009-0.042)

PMID:41162813 · one of two readings recorded this

BPQ score

no effect, p = 0.708

BPQ | 93.47 (81.70, 105.23) | 87.13 (75.37, 98.90) | 91.73 (79.97, 103.50) | 96.73 (84.97, 108.50) | 0.708 | 89.45 (83.43, 95.47) | 95.08 (88.71, 101.46) | 0.006 | 0.838

PMID:41651893 · one of two readings recorded this

BPQ score

no effect, p = 0.838

BPQ | 93.47 (81.70, 105.23) | 87.13 (75.37, 98.90) | 91.73 (79.97, 103.50) | 96.73 (84.97, 108.50) | 0.708 | 89.45 (83.43, 95.47) | 95.08 (88.71, 101.46) | 0.006 | 0.838

PMID:41651893 · one of two readings recorded this

BPQ score

increases, p = 0.006

BPQ | 93.47 (81.70, 105.23) | 87.13 (75.37, 98.90) | 91.73 (79.97, 103.50) | 96.73 (84.97, 108.50) | 0.708 | 89.45 (83.43, 95.47) | 95.08 (88.71, 101.46) | 0.006 | 0.838

PMID:41651893 · one of two readings recorded this

correlation of RPE with change in BPQ score

increases, p = 0.005

Significant positive correlations are observed between RPE scores, VO2max, and changes in BPQ score (p = 0.005; p = 0.034)

PMID:41651893 · one of two readings recorded this

correlation of VO2max with change in BPQ score

increases, p = 0.034

Significant positive correlations are observed between RPE scores, VO2max, and changes in BPQ score (p = 0.005; p = 0.034)

PMID:41651893 · one of two readings recorded this

interoception after acute exhaustive exercise, Body Perception Questionnaire short form (BPQ-SF) and MAIA subscales; exercise capacity (time to exhaustion, VO2max) on the Bruce incremental treadmill test

no effect

Not recorded as a finding: this platform holds no node for the endpoint

No significant differences in interoception scores during exercise were observed among the groups (all p values > 0.05), indicating relatively comparable interoception scores across the control, PQQ, NMN, and PN groups.

PMID:41651893 · one of two readings recorded this

interoception after acute exhaustive treadmill exercise, Body Perception Questionnaire short form total score and MAIA-2 subscale scores, NMN 300 mg arm versus placebo arm (also reported: exercise capacity indicators TTE, VO2max, peak RER by Bruce protocol, with no sentence naming NMN)

no effect, all group p values > 0.05

Not recorded as a finding: this platform holds no node for the endpoint

No significant differences in interoception scores during exercise were observed among the groups (all p values > 0.05), indicating relatively comparable interoception scores across the control, PQQ, NMN, and PN groups.

PMID:41651893 · one of two readings recorded this

MAIA Attention Regulation

no effect, p = 0.336

Attention Regulation | 2.51 (2.11, 2.91) | 2.58 (2.18, 2.98) | 2.96 (2.56, 3.36) | 2.52 (2.12, 2.92) | 0.336 | 2.61 (2.41, 2.81) | 2.68 (2.45, 2.91) | 0.413 | 0.446

PMID:41651893 · one of two readings recorded this

MAIA Attention Regulation

no effect, p = 0.446

Attention Regulation | 2.51 (2.11, 2.91) | 2.58 (2.18, 2.98) | 2.96 (2.56, 3.36) | 2.52 (2.12, 2.92) | 0.336 | 2.61 (2.41, 2.81) | 2.68 (2.45, 2.91) | 0.413 | 0.446

PMID:41651893 · one of two readings recorded this

MAIA Attention Regulation

no effect, p = 0.413

Attention Regulation | 2.51 (2.11, 2.91) | 2.58 (2.18, 2.98) | 2.96 (2.56, 3.36) | 2.52 (2.12, 2.92) | 0.336 | 2.61 (2.41, 2.81) | 2.68 (2.45, 2.91) | 0.413 | 0.446

PMID:41651893 · one of two readings recorded this

MAIA Body Listening

no effect, p = 0.75

Body Listening | 2.41 (1.98, 2.85) | 2.54 (2.11, 2.98) | 2.75 (2.31, 3.18) | 2.54 (2.11, 2.98) | 0.750 | 2.36 (2.12, 2.61) | 2.76 (2.52, 3.01) | < 0.001 | 0.016 PLC: pre vs. post (p-value = 0.380) PQQ: pre vs. post (p-value < 0.001) NMN: pre vs. post (p-value = 0.102) PN: pre vs. post (p-value = 0.011)

PMID:41651893 · one of two readings recorded this

MAIA Body Listening

modulates, p = 0.016

body listening was the only domain to have exhibited a significant group × time interaction effect (p = 0.016)

PMID:41651893 · one of two readings recorded this

MAIA Body Listening

increases, p = 0.001

Body Listening | 2.41 (1.98, 2.85) | 2.54 (2.11, 2.98) | 2.75 (2.31, 3.18) | 2.54 (2.11, 2.98) | 0.750 | 2.36 (2.12, 2.61) | 2.76 (2.52, 3.01) | < 0.001 | 0.016 PLC: pre vs. post (p-value = 0.380) PQQ: pre vs. post (p-value < 0.001) NMN: pre vs. post (p-value = 0.102) PN: pre vs. post (p-value = 0.011)

PMID:41651893 · one of two readings recorded this

MAIA Body Listening

no effect, p = 0.102

no significant change in the NMN group (p = 0.102)

PMID:41651893 · one of two readings recorded this

MAIA Body Listening

no effect, p = 0.38

no significant change in the placebo group (p = 0.380)

PMID:41651893 · one of two readings recorded this

MAIA Body Listening

increases, p = 0.011

a significant improvement in the PN group (p = 0.011)

PMID:41651893 · one of two readings recorded this

MAIA Body Listening

increases, p = 0.001

a significant improvement in the PQQ group (p < 0.001)

PMID:41651893 · one of two readings recorded this

MAIA Emotional Awareness

no effect, p = 0.589

Emotional Awareness | 2.81 (2.40, 3.22) | 2.85 (2.44, 3.26) | 3.15 (2.74, 3.56) | 3.05 (2.64, 3.46) | 0.589 | 2.96 (2.72, 3.19) | 2.98 (2.78, 3.18) | 0.785 | 0.440

PMID:41651893 · one of two readings recorded this

MAIA Emotional Awareness

no effect, p = 0.44

Emotional Awareness | 2.81 (2.40, 3.22) | 2.85 (2.44, 3.26) | 3.15 (2.74, 3.56) | 3.05 (2.64, 3.46) | 0.589 | 2.96 (2.72, 3.19) | 2.98 (2.78, 3.18) | 0.785 | 0.440

PMID:41651893 · one of two readings recorded this

MAIA Emotional Awareness

no effect, p = 0.785

Emotional Awareness | 2.81 (2.40, 3.22) | 2.85 (2.44, 3.26) | 3.15 (2.74, 3.56) | 3.05 (2.64, 3.46) | 0.589 | 2.96 (2.72, 3.19) | 2.98 (2.78, 3.18) | 0.785 | 0.440

PMID:41651893 · one of two readings recorded this

MAIA Not-Distracting

no effect, p = 0.768

Not-Distracting | 2.54 (2.08, 2.99) | 2.23 (1.78, 2.69) | 2.26 (1.81, 2.72) | 2.40 (1.94, 2.86) | 0.768 | 2.42 (2.16, 2.30) | 2.30 (2.06, 2.53) | 0.238 | 0.953

PMID:41651893 · one of two readings recorded this

MAIA Not-Distracting

no effect, p = 0.953

Not-Distracting | 2.54 (2.08, 2.99) | 2.23 (1.78, 2.69) | 2.26 (1.81, 2.72) | 2.40 (1.94, 2.86) | 0.768 | 2.42 (2.16, 2.30) | 2.30 (2.06, 2.53) | 0.238 | 0.953

PMID:41651893 · one of two readings recorded this

MAIA Not-Distracting

no effect, p = 0.238

Not-Distracting | 2.54 (2.08, 2.99) | 2.23 (1.78, 2.69) | 2.26 (1.81, 2.72) | 2.40 (1.94, 2.86) | 0.768 | 2.42 (2.16, 2.30) | 2.30 (2.06, 2.53) | 0.238 | 0.953

PMID:41651893 · one of two readings recorded this

MAIA Not-Worrying

no effect, p = 0.62

Not-Worrying | 2.63 (2.29, 2.97) | 2.55 (2.21, 2.89) | 2.47 (2.13, 2.81) | 2.32 (1.98, 2.66) | 0.620 | 2.53 (2.34, 2.46) | 2.46 (2.26, 2.65) | 0.415 | 0.442

PMID:41651893 · one of two readings recorded this

MAIA Not-Worrying

no effect, p = 0.442

Not-Worrying | 2.63 (2.29, 2.97) | 2.55 (2.21, 2.89) | 2.47 (2.13, 2.81) | 2.32 (1.98, 2.66) | 0.620 | 2.53 (2.34, 2.46) | 2.46 (2.26, 2.65) | 0.415 | 0.442

PMID:41651893 · one of two readings recorded this

MAIA Not-Worrying

no effect, p = 0.415

Not-Worrying | 2.63 (2.29, 2.97) | 2.55 (2.21, 2.89) | 2.47 (2.13, 2.81) | 2.32 (1.98, 2.66) | 0.620 | 2.53 (2.34, 2.46) | 2.46 (2.26, 2.65) | 0.415 | 0.442

PMID:41651893 · one of two readings recorded this

MAIA Noticing

no effect, p = 0.375

Noticing | 2.81 (2.28, 3.33) | 3.18 (2.65, 3.70) | 3.45 (2.92, 3.98) | 3.02 (2.49, 3.54) | 0.375 | 3.13 (2.83, 3.43) | 3.09 (2.81, 3.37) | 0.729 | 0.711

PMID:41651893 · one of two readings recorded this

MAIA Noticing

no effect, p = 0.711

Noticing | 2.81 (2.28, 3.33) | 3.18 (2.65, 3.70) | 3.45 (2.92, 3.98) | 3.02 (2.49, 3.54) | 0.375 | 3.13 (2.83, 3.43) | 3.09 (2.81, 3.37) | 0.729 | 0.711

PMID:41651893 · one of two readings recorded this

MAIA Noticing

no effect, p = 0.729

Noticing | 2.81 (2.28, 3.33) | 3.18 (2.65, 3.70) | 3.45 (2.92, 3.98) | 3.02 (2.49, 3.54) | 0.375 | 3.13 (2.83, 3.43) | 3.09 (2.81, 3.37) | 0.729 | 0.711

PMID:41651893 · one of two readings recorded this

MAIA Self-Regulation

no effect, p = 0.219

Self-Regulation | 2.58 (2.17, 3.00) | 2.98 (2.56, 3.39) | 3.20 (2.78, 3.62) | 2.86 (2.44, 3.28) | 0.219 | 2.79 (2.56, 3.02) | 3.02 (2.79, 3.25) | 0.015 | 0.464

PMID:41651893 · one of two readings recorded this

MAIA Self-Regulation

no effect, p = 0.464

Self-Regulation | 2.58 (2.17, 3.00) | 2.98 (2.56, 3.39) | 3.20 (2.78, 3.62) | 2.86 (2.44, 3.28) | 0.219 | 2.79 (2.56, 3.02) | 3.02 (2.79, 3.25) | 0.015 | 0.464

PMID:41651893 · one of two readings recorded this

MAIA Self-Regulation

increases, p = 0.015

Self-Regulation | 2.58 (2.17, 3.00) | 2.98 (2.56, 3.39) | 3.20 (2.78, 3.62) | 2.86 (2.44, 3.28) | 0.219 | 2.79 (2.56, 3.02) | 3.02 (2.79, 3.25) | 0.015 | 0.464

PMID:41651893 · one of two readings recorded this

MAIA total score

no effect, p = 0.259

MAIA score | 97.87 (90.46, 105.27) | 99.90 (92.49, 107.31) | 107.37 (99.96, 114.77) | 98.77 (91.36, 106.17) | 0.259 | 99.88 (96.08, 103.69) | 102.07 (97.98, 106.15) | 0.114 | 0.119

PMID:41651893 · one of two readings recorded this

MAIA total score

no effect, p = 0.119

MAIA score | 97.87 (90.46, 105.27) | 99.90 (92.49, 107.31) | 107.37 (99.96, 114.77) | 98.77 (91.36, 106.17) | 0.259 | 99.88 (96.08, 103.69) | 102.07 (97.98, 106.15) | 0.114 | 0.119

PMID:41651893 · one of two readings recorded this

MAIA total score

no effect, p = 0.114

MAIA score | 97.87 (90.46, 105.27) | 99.90 (92.49, 107.31) | 107.37 (99.96, 114.77) | 98.77 (91.36, 106.17) | 0.259 | 99.88 (96.08, 103.69) | 102.07 (97.98, 106.15) | 0.114 | 0.119

PMID:41651893 · one of two readings recorded this

MAIA Trusting

no effect, p = 0.505

Trusting | 3.02 (2.58, 3.46) | 3.06 (2.61, 3.50) | 3.37 (2.93, 3.81) | 2.91 (2.47, 3.35) | 0.505 | 2.97 (2.74, 3.19) | 3.21 (2.95, 3.48) | 0.031 | 0.540

PMID:41651893 · one of two readings recorded this

MAIA Trusting

no effect, p = 0.54

Trusting | 3.02 (2.58, 3.46) | 3.06 (2.61, 3.50) | 3.37 (2.93, 3.81) | 2.91 (2.47, 3.35) | 0.505 | 2.97 (2.74, 3.19) | 3.21 (2.95, 3.48) | 0.031 | 0.540

PMID:41651893 · one of two readings recorded this

MAIA Trusting

increases, p = 0.031

Trusting | 3.02 (2.58, 3.46) | 3.06 (2.61, 3.50) | 3.37 (2.93, 3.81) | 2.91 (2.47, 3.35) | 0.505 | 2.97 (2.74, 3.19) | 3.21 (2.95, 3.48) | 0.031 | 0.540

PMID:41651893 · one of two readings recorded this

peak respiratory exchange ratio (RER)

no effect, p = 0.281

Peak RER | 1.10 (1.08, 1.13) | 1.15 (1.10, 1.19) | 1.09 (1.07, 1.11) | 1.17 (1.14, 1.21) | 1.10 (1.08, 1.11) | 1.17 (1.14, 1.21) | 1.10 (1.07, 1.12) | 1.16 (1.11, 1.21) | 1.311 | 0.281 | 0.070 | M

PMID:41651893 · one of two readings recorded this

respiratory efficiency (VEmax/VO2max)

no effect, p = 0.98

VEmax/VO₂max | 31.98 (30.20, 33.76) | 32.42 (30.13, 34.71) | 30.93 (29.20, 32.65) | 31.57 (29.74, 33.41) | 32.18 (30.69, 33.67) | 32.37 (31.05, 33.70) | 31.37 (29.75, 32.98) | 31.56 (28.56, 34.56) | 0.061 | 0.980 | 0.004 | -

PMID:41651893 · one of two readings recorded this

time to anaerobic threshold (AT)

no effect, p = 0.47

AT (s) | 528.53 (487.91, 569.16) | 476.60 (410.17, 543.03) | 508.67 (470.64, 546.69) | 471.40 (403.54, 539.26) | 530.40 (486.57, 574.23) | 502.80 (433.52, 572.08) | 489.00 (449.45, 528.55) | 461.87 (398.07, 525.67) | 0.855 | 0.470 | 0.047 | S

PMID:41651893 · one of two readings recorded this

time to exhaustion (TTE)

no effect, p = 0.578

TTE (s) | 963.20 (909.94, 1016.46) | 957.33 (899.67, 1014.99) | 940.00 (900.00, 980.00) | 941.27 (885.28, 997.25) | 972.13 (918.21 1026.06) | 939.60 (887.72, 991.48) | 970.07 (916.88, 1023.26) | 926.13 (888.43, 963.84) | 0.665 | 0.578 | 0.037 | S

PMID:41651893 · one of two readings recorded this

VO2 at anaerobic threshold (VO2AT)

no effect, p = 0.496

VO2AT (mL/ kg·min) | 37.00 (34.25, 39.75) | 35.47 (31.54, 39.39) | 37.17 (34.92, 39.41) | 34.20 (30.05, 38.35) | 38.57 (35.34, 41.81) | 37.87 (32.82, 42.91) | 37.00 (34.17, 39.83) | 34.60 (30.17, 39.03) | 0.806 | 0.496 | 0.044 | S

PMID:41651893 · one of two readings recorded this

VO2 utilization (VO2 at AT/VO2max)

no effect, p = 0.66

VO₂ Utilization (%) | 67.60 (62.51, 72.69) | 66.28 (59.84, 72.71) | 68.29 (63.58, 73.00) | 68.40 (64.21, 72.59) | 70.78 (65.00, 76.55) | 70.35 (65.84, 74.86) | 67.13 (61.84, 72.42) | 68.05 (61.86, 74.25) | 0.53 | 0.66 | 0.03 | S

PMID:41651893 · one of two readings recorded this

VO2max

no effect, p = 0.508

VO2max (mL/ kg·min) | 54.80 (53.08, 56.52) | 56.40 (53.17, 59.63) | 54.60 (53.01, 56.19) | 54.47 (52.45, 56.48) | 54.53 (52.81, 56.26) | 54.67 (52.49, 56.84) | 55.20 (53.51, 56.89) | 54.73 (52.20, 57.27) | 0.784 | 0.508 | 0.043 | S

PMID:41651893 · one of two readings recorded this

BFR-exercise-induced muscle necrosis

increases

BFR-exercise-induced significant muscle necrosis at 0 h, which resolved within 24 h in both conditions

PMID:41705654 · one of two readings recorded this

mitochondrial content adaptation after BFR-exercise

decreases

However, this adaptation was abolished with NMN

PMID:41705654 · one of two readings recorded this

mitochondrial content in exercised muscle after BFR-exercise

increases

BFR-exercise increased the mitochondrial content in exercised muscle by 171% after 24 h of recovery

PMID:41705654 · one of two readings recorded this

p21 mRNA rise after exercise

decreases

NMN supplementation suppressed exercise-induced increases in TNF-α and IL-10 mRNA but delayed the rise in p21 mRNA

PMID:41705654 · one of two readings recorded this

resolution of infiltrating cells from necrotic regions

decreases

The resolution of infiltrating cells from necrotic regions was moderately delayed by NMN

PMID:41705654 · one of two readings recorded this

TNF-α and IL-10 mRNA expression in human skeletal muscle biopsies before and after blood-flow-restriction resistance exercise, NMN 1200 mg/d versus placebo, crossover

decreases

Not recorded as a finding: a node exists but the paper states a different instrument or population

NMN supplementation suppressed exercise-induced increases in TNF-α and IL-10 mRNA but delayed the rise in p21 mRNA, suggesting attenuated inflammatory signaling and delayed myogenic differentiation.

PMID:41705654 · one of two readings recorded this

TNF-α and IL-10 mRNA increase after exercise

decreases

NMN supplementation suppressed exercise-induced increases in TNF-α and IL-10 mRNA but delayed the rise in p21 mRNA

PMID:41705654 · one of two readings recorded this

TNF-α, IL-10 and p21 mRNA expression in vastus lateralis muscle biopsies after blood flow restriction-resistance exercise, with mitochondrial content and infiltrating-cell resolution

decreases

Not recorded as a finding: this platform holds no node for the endpoint

NMN supplementation suppressed exercise-induced increases in TNF-α and IL-10 mRNA but delayed the rise in p21 mRNA, suggesting attenuated inflammatory signaling and delayed myogenic differentiation.

PMID:41705654 · one of two readings recorded this

resting diastolic blood pressure

decreases, n = 349

reduction of 2.15 mmHg in DBP (95% CI: −3.68 to −0.61), without observed heterogeneity (I2 = 0.0%)

PMID:41901064 · one of two readings recorded this

resting diastolic blood pressure

no effect

baseline DBP of 80 mmHg or greater (WMD: −2.34 mmHg; 95% CI: −5.62 to 0.93)

PMID:41901064 · one of two readings recorded this

resting diastolic blood pressure

no effect

those with a BMI of 25 kg/m2 or greater (WMD: −1.84 mmHg; 95% CI: −3.87 to 0.19)

PMID:41901064 · one of two readings recorded this

resting diastolic blood pressure

no effect

daily NMN dosage exceeding 300 mg (WMD: −2.23 mmHg; 95% CI: −4.73 to 0.28)

PMID:41901064 · one of two readings recorded this

resting diastolic blood pressure

decreases

DBP (WMD: −2.32 mmHg; 95% CI: −4.00 to −0.65; I2 = 0.0%)

PMID:41901064 · one of two readings recorded this

resting diastolic blood pressure

no effect

interventions lasting less than 10 weeks (WMD: −2.23 mmHg; 95% CI: −4.73 to 0.28)

PMID:41901064 · one of two readings recorded this

resting diastolic blood pressure

no effect

participants younger than 60 years old (WMD: −2.15 mmHg; 95% CI: −4.51 to 0.21)

PMID:41901064 · one of two readings recorded this

resting systolic blood pressure, pooled WMD

WMD -1.58 mmHg; 95% CI -3.69 to 0.53

Not recorded as a finding: Sentence states a slight reduction that was not statistically significant; not a two-sided null statement, so no direction is recordable

Although a slight reduction in SBP (WMD: −1.58 mmHg; 95% CI: −3.69 to 0.53; I2 = 15.5%) was observed after NMN supplementation, the common-effects model indicated that this decrease was not statistically significant.

PMID:41901064 · one of two readings recorded this

resting systolic blood pressure

no effect, n = 349

Although a slight reduction in SBP (WMD: −1.58 mmHg; 95% CI: −3.69 to 0.53; I2 = 15.5%)

PMID:41901064 · one of two readings recorded this

resting systolic blood pressure

decreases

participants aged 60 years and older (WMD: −3.94 mmHg; 95% CI: −7.06 to −0.82)

PMID:41901064 · one of two readings recorded this

resting systolic blood pressure

decreases

SBP in the overall adult population (WMD: −2.73 mmHg; 95% CI: −5.11 to −0.35; I2 = 0.0%)

PMID:41901064 · one of two readings recorded this

resting systolic blood pressure

decreases

studies conducted in non-Asian countries (WMD: −4.07 mmHg; 95% CI: −7.58 to −0.56)

PMID:41901064 · one of two readings recorded this

body mass index

no effect, p = 0.795

MD = 0.02 kg/m2, 95% CI −0.14 to 0.18, p = 0.795, I2 = 0%

PMID:42514320 · one of two readings recorded this

alanine aminotransferase (ALT)

no effect, p = 0.169

MD = −1.03 U/L, 95% CI −2.51 to 0.44, p = 0.169, I2 = 0%

PMID:42514320 · one of two readings recorded this

aspartate aminotransferase (AST)

no effect, p = 0.686

MD = −0.24 U/L, 95% CI −1.43 to 0.94, p = 0.686, I2 = 0%

PMID:42514320 · one of two readings recorded this

body weight

no effect, p = 0.462

MD = −0.32 kg, 95% CI −1.19 to 0.54, p = 0.462, I2 = 14.7%

PMID:42514320 · one of two readings recorded this

diastolic blood pressure

decreases, p = 0.007, n = 339

The diastolic blood pressure analysis also included 11 comparisons with 339 participants. NMN supplementation was associated with a small but significant reduction in diastolic blood pressure (MD = −2.43 mmHg, 95% CI −4.21 to −0.66, p = 0.007, I2 = 0%)

PMID:42514320 · one of two readings recorded this

diastolic blood pressure

decreases, p = 0.033

(MD = −2.02 mmHg, 95% CI −3.87 to −0.16, p = 0.033)

PMID:42514320 · one of two readings recorded this

diastolic blood pressure

decreases

participants aged 60 years or older (MD = −3.18 mmHg, 95% CI −6.19 to −0.16)

PMID:42514320 · one of two readings recorded this

diastolic blood pressure

decreases

(MD = −2.63 mmHg, 95% CI −4.90 to −0.35)

PMID:42514320 · one of two readings recorded this

diastolic blood pressure

decreases

(MD = −3.61 mmHg, 95% CI −6.74 to −0.47)

PMID:42514320 · one of two readings recorded this

fasting plasma glucose

no effect, p = 0.492

MD = 0.73 mg/dL, 95% CI −1.36 to 2.82, p = 0.492, I2 = 0%

PMID:42514320 · one of two readings recorded this

glycated hemoglobin

no effect, p = 0.342

MD = 0.03%, 95% CI −0.04 to 0.10, p = 0.342, I2 = 22.4%

PMID:42514320 · one of two readings recorded this

HOMA-IR dose subgroup difference

no effect, p = 0.9344

Dose subgroup analysis showed no significant subgroup difference (χ2 = 0.14, df = 2, p = 0.9344)

PMID:42514320 · one of two readings recorded this

HOMA-IR duration subgroup difference

no effect, p = 0.4958

intervention-duration subgroup analysis also showed no significant difference (χ2 = 0.46, df = 1, p = 0.4958)

PMID:42514320 · one of two readings recorded this

HOMA-IR (mean difference in change from baseline)

no effect, p = 0.19

MD = −0.22, 95% CI −0.55 to 0.11, p = 0.19, I2 = 0.0%

PMID:42514320 · one of two readings recorded this

HOMA-IR (standardized mean difference sensitivity analysis)

no effect

SMD = −0.24, 95% CI −0.58 to 0.09, I2 = 0.0%

PMID:42514320 · one of two readings recorded this

serious adverse events (Peto odds ratio)

no effect, p = 0.443

Peto OR = 0.61, 95% CI 0.18 to 2.14, p = 0.443, I2 = 0%

PMID:42514320 · one of two readings recorded this

serious adverse events (risk difference)

no effect, p = 0.878

RD = −0.003, 95% CI −0.036 to 0.031, p = 0.878, I2 = 0%

PMID:42514320 · one of two readings recorded this

systolic blood pressure, pooled brachial BP, setting not stated

no effect, MD -0.89 mmHg, 95% CI -3.83 to 2.05, p = 0.553

Not recorded as a finding: The only whole-population sentence is agentless and never names NMN; the node exists (systolic-blood-pressure-unspecified-setting) but quote rule 1 stops it.

The overall effect was not statistically significant (MD = −0.89 mmHg, 95% CI −3.83 to 2.05, p = 0.553), with moderate between-study heterogeneity (I2 = 46.3%).

PMID:42514320 · one of two readings recorded this

systolic blood pressure

no effect, p = 0.553, n = 339

The systolic blood pressure analysis included 11 comparisons with 339 participants. The overall effect was not statistically significant (MD = −0.89 mmHg, 95% CI −3.83 to 2.05, p = 0.553)

PMID:42514320 · one of two readings recorded this

systolic blood pressure

no effect, p = 0.081

(MD = −2.00 mmHg, 95% CI −4.24 to 0.24, p = 0.081)

PMID:42514320 · one of two readings recorded this

systolic blood pressure

decreases

participants aged 60 years or older (MD = −4.40 mmHg, 95% CI −8.61 to −0.20)

PMID:42514320 · one of two readings recorded this

systolic blood pressure

decreases

in metabolic-risk populations (MD = −5.07 mmHg, 95% CI −8.64 to −1.51)

PMID:42514320 · one of two readings recorded this

total adverse events

no effect, p = 0.761

RD = −0.008, 95% CI −0.061 to 0.045, p = 0.761, I2 = 0%

PMID:42514320 · one of two readings recorded this

withdrawals due to adverse events

no effect, p = 0.95

RD = −0.001, 95% CI −0.036 to 0.034, p = 0.950, I2 = 0%

PMID:42514320 · one of two readings recorded this